About this Research Topic
Acute Myeloid Leukemia (AML) is a complex and heterogeneous blood cancer that poses significant challenges for both patients and clinicians. Recent years have witnessed a transformative shift in AML research driven by the principles of precision medicine, with a specific spotlight on the crucial role played by biomarkers. This research area delves into the intricate landscape of biomarkers within the context of AML, which can be molecular, genetic, epigenetic, or protein-based in origin. The emphasis is on unraveling new avenues for cell therapy and immunotherapy through the exploration of these biomarkers, which often surpass their diagnostic value, evolving into indispensable tools for tailoring treatments to individual patients. Their significance in AML lies in their ability to guide personalized treatment selection.
The primary objective of this Research Topic is to collate the latest insights into novel targets for cell therapy and immunotherapy in AML. We invite contributions that unveil new biomarkers linked to distinct AML subtypes, explore the therapeutic potential of these markers through preclinical investigations, and validate their utility in clinically relevant settings. The unifying theme among all submissions should be the exploration of biomarkers as pivotal instruments for the advancement of cell therapies and immunotherapies in the context of AML. Despite the immense promise offered by biomarkers in AML treatment, several challenges remain, including the need for standardized testing methodologies and addressing issues related to disease heterogeneity and treatment resistance. The quest for innovative approaches, including the identification of novel biomarkers, holds the key to surmounting these challenges and propelling the field forward.
This Research Topic will provide a comprehensive exploration of the role of biomarkers in AML treatment, with a specific focus on their relevance to cell therapy and immunotherapy. We invite authors who possess a deep understanding of AML to contribute their latest advancements and discoveries to this collection. The central theme revolves around the identification of new therapeutic targets. By fostering collaboration between researchers and clinicians, we aspire to uncover innovative strategies that harness the full potential of biomarkers, leading to more effective and personalized approaches in the treatment of AML. This collection of Original Research articles, Reviews, Mini Reviews, Systematic Reviews, Case Reports, Perspectives, Short communications, or Clinical Trials will enable benchmarking of current progress in AML clinical management and contribute to future transformative precision medicines and biomarker-driven therapies in AML.
The primary objective of this Research Topic is to collate the latest insights into novel targets for cell therapy and immunotherapy in AML. We invite contributions that unveil new biomarkers linked to distinct AML subtypes, explore the therapeutic potential of these markers through preclinical investigations, and validate their utility in clinically relevant settings. The unifying theme among all submissions should be the exploration of biomarkers as pivotal instruments for the advancement of cell therapies and immunotherapies in the context of AML. Despite the immense promise offered by biomarkers in AML treatment, several challenges remain, including the need for standardized testing methodologies and addressing issues related to disease heterogeneity and treatment resistance. The quest for innovative approaches, including the identification of novel biomarkers, holds the key to surmounting these challenges and propelling the field forward.
This Research Topic will provide a comprehensive exploration of the role of biomarkers in AML treatment, with a specific focus on their relevance to cell therapy and immunotherapy. We invite authors who possess a deep understanding of AML to contribute their latest advancements and discoveries to this collection. The central theme revolves around the identification of new therapeutic targets. By fostering collaboration between researchers and clinicians, we aspire to uncover innovative strategies that harness the full potential of biomarkers, leading to more effective and personalized approaches in the treatment of AML. This collection of Original Research articles, Reviews, Mini Reviews, Systematic Reviews, Case Reports, Perspectives, Short communications, or Clinical Trials will enable benchmarking of current progress in AML clinical management and contribute to future transformative precision medicines and biomarker-driven therapies in AML.
Keywords: therapeutic targets, acute myeloid leukemia, biomarkers, cell therapy, precision medicine, chemotherapy resistance, immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
